Legend Biotech (LEGN) Other Non-Current Liabilities (2020 - 2026)

Legend Biotech (LEGN) has 7 years of Other Non-Current Liabilities data on file, last reported at $7.8 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 28.76% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 28.76% YoY) and the FY2025 annual result came in at $8.0 million, up 31.15% from the prior year.
• Other Non-Current Liabilities declined to $7.8 million in Q1 2026, from $8.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $8.1 million in Q3 2025 to a low of $1.9 million in Q1 2022.
• A 5-year average of $6.7 million and a median of $6.9 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 95121.15% — and 2024, when it retreated 16.5%.
• Tracing LEGN's Other Non-Current Liabilities over 5 years: stood at $7.7 million in 2022, then dropped by 4.62% to $7.3 million in 2023, then dropped by 16.5% to $6.1 million in 2024, then surged by 31.15% to $8.0 million in 2025, then retreated by 2.5% to $7.8 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $7.8 million (Q1 2026), $8.0 million (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.